{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:35:12Z","timestamp":1794486912875,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018217","name":"Federal University of Sao Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.medj.2025.100747","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:40:42Z","timestamp":1748342442000},"page":"100747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Felipe","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Fernandes de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Ang\u00e9lica","family":"Estev\u00e3o de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Oliveira","family":"Pesquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Zago","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante Akira","family":"Kondo Kuroiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Korn","family":"Malerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Atala","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilva Bueno","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Eid","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Buchele","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-6365","authenticated-orcid":false,"given":"Jayakrishna","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100747_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of Diabetic Retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib2","series-title":"IDF Diabetes Atlas","year":"2025"},{"key":"10.1016\/j.medj.2025.100747_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100747_bib4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100747_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.oret.2017.12.006","article-title":"Medicare Spending on Anti-Vascular Endothelial Growth Factor Medications","volume":"2","author":"Patel","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.medj.2025.100747_bib6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ophtha.2019.04.037","article-title":"Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor","volume":"126","author":"Storey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.medj.2025.100747_bib7","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2021097","article-title":"Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology","volume":"43","author":"Mun","year":"2021","journal-title":"Epidemiol. Health"},{"key":"10.1016\/j.medj.2025.100747_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2023","journal-title":"Syst. Rev."},{"key":"10.1016\/j.medj.2025.100747_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/DMSO.S214098","article-title":"Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia","volume":"12","author":"Spooner","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.medj.2025.100747_bib11","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet Global Health Commission on Global Eye Health: vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.medj.2025.100747_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj3658","article-title":"Alu complementary DNA is enriched in atrophic macular degeneration and triggers retinal pigmented epithelium toxicity via cytosolic innate immunity","volume":"7","author":"Fukuda","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.medj.2025.100747_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMra1510092","article-title":"Mobile DNA in Health and Disease","volume":"377","author":"Kazazian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100747_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022751118","article-title":"Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration","volume":"118","author":"Fukuda","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2025.100747_bib15","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-020-18528-z","article-title":"Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development","volume":"11","author":"Ambati","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100747_bib16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMcibr1204973","article-title":"Eyeing macular degeneration--few inflammatory remarks","volume":"367","author":"Rosenbaum","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100747_bib17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1261754","article-title":"Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity","volume":"346","author":"Fowler","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.medj.2025.100747_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2025.100747_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080029","article-title":"Dicer expression exhibits a tissue-specific diurnal pattern that is lost during aging and in diabetes","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2025.100747_bib20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100747_bib21","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/ijms20092101","article-title":"Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7","volume":"20","author":"Pavlou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2025.100747_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.64.5.3","article-title":"Kamuvudine-9 Protects Retinal Structure and Function in a Novel Model of Experimental Rhegmatogenous Retinal Detachment","volume":"64","author":"Huang","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.medj.2025.100747_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-021-00537-z","article-title":"Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-\u03b2 induced retinal pigmented epithelium degeneration","volume":"6","author":"Narendran","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2025.100747_bib24","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1167\/iovs.15-17440","article-title":"Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice","volume":"56","author":"Mizutani","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.medj.2025.100747_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi4493","article-title":"DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs","volume":"6","author":"Wang","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.medj.2025.100747_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41419-022-04786-w","article-title":"Targeted P2X7\/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy","volume":"13","author":"Kong","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.medj.2025.100747_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112419","article-title":"Oridonin attenuates diabetic retinopathy progression by suppressing NLRP3 inflammasome pathway","volume":"596","author":"Zhang","year":"2025","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.medj.2025.100747_bib28","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1167\/iovs.03-1062","article-title":"Enhancement of P2X(7)-induced pore formation and apoptosis: an early effect of diabetes on the retinal microvasculature","volume":"45","author":"Sugiyama","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.medj.2025.100747_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and External Controls in Clinical Trials - A Primer for Researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.medj.2025.100747_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2147\/OPTH.S100764","article-title":"Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials","volume":"10","author":"Dugel","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0022-3476(99)70400-2","article-title":"The \u201cinclusion benefit\u201d in clinical trials","volume":"134","author":"Lantos","year":"1999","journal-title":"J. Pediatr."},{"key":"10.1016\/j.medj.2025.100747_bib32","article-title":"Efficacy and safety of dexamethasone or triamcinolone in combination with anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis with trial sequential analysis","volume":"20","author":"Zhou","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2025.100747_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib34","article-title":"Anti-VEGF Monotherapy vs Anti-VEGF and Steroid Combination Therapy for Diabetic Macular Edema: A Meta-analysis","volume":"9","author":"Grad","year":"2024","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.medj.2025.100747_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00592-019-01416-4","article-title":"Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results","volume":"56","author":"Busch","year":"2019","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.medj.2025.100747_bib36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/24741264221138722","article-title":"Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review","volume":"7","author":"Wang","year":"2023","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.medj.2025.100747_bib38","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1167\/iovs.16-20356","article-title":"Report From the NEI\/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop","volume":"57","author":"Nair","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.medj.2025.100747_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0000000000001660","article-title":"Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection","volume":"78","author":"Quercia","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.medj.2025.100747_bib40","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2025.100747_bib41","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/135965350701200704","article-title":"Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors","volume":"12","author":"Venhoff","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.medj.2025.100747_bib42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","article-title":"Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy","volume":"21","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.medj.2025.100747_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","article-title":"Mitochondrial toxicity of antiviral drugs","volume":"1","author":"Lewis","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2025.100747_bib44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/17425255.2010.526602","article-title":"Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA","volume":"6","author":"Koczor","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.medj.2025.100747_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data","volume":"172","author":"Gonzalez","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.medj.2025.100747_bib46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jama.2022.25029","article-title":"Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy","volume":"329","author":"Maturi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100747_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaophthalmol.2014.3600","article-title":"Randomizing 1 eye or 2 eyes: a missed opportunity","volume":"133","author":"Glassman","year":"2015","journal-title":"JAMA Ophthalmol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:40:16Z","timestamp":1757778016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666634025001746"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100747","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100747"}}